CARA vs. SCPH, RGLS, SYRS, RAPT, CYBN, CNTX, CRVS, CTMX, INCR, and GOSS
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include scPharmaceuticals (SCPH), Regulus Therapeutics (RGLS), Syros Pharmaceuticals (SYRS), RAPT Therapeutics (RAPT), Cybin (CYBN), Context Therapeutics (CNTX), Corvus Pharmaceuticals (CRVS), CytomX Therapeutics (CTMX), InterCure (INCR), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry.
Cara Therapeutics (NASDAQ:CARA) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Cara Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500.
scPharmaceuticals has a net margin of -327.29% compared to Cara Therapeutics' net margin of -723.49%. scPharmaceuticals' return on equity of -132.39% beat Cara Therapeutics' return on equity.
In the previous week, Cara Therapeutics' average media sentiment score of 0.00 equaled scPharmaceuticals'average media sentiment score.
44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
scPharmaceuticals has lower revenue, but higher earnings than Cara Therapeutics. scPharmaceuticals is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cara Therapeutics presently has a consensus price target of $11.12, suggesting a potential upside of 1,681.48%. scPharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 406.67%. Given Cara Therapeutics' higher probable upside, equities research analysts plainly believe Cara Therapeutics is more favorable than scPharmaceuticals.
Cara Therapeutics received 510 more outperform votes than scPharmaceuticals when rated by MarketBeat users. Likewise, 75.03% of users gave Cara Therapeutics an outperform vote while only 66.24% of users gave scPharmaceuticals an outperform vote.
Summary
scPharmaceuticals beats Cara Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
